Medicare kidney spending reaches crucial moment

September 4, 2012
Dialysis and drugs to control anemia became one of Medicare’s biggest costs after 1972, when the program expanded to care for anyone in the country who needed treatment, regardless of age. Credit: Mike Cohea/Brown University

Amid a presidential campaign and facing the "fiscal cliff," Americans hear a lot about federal spending, particularly for Medicare. But few probably know of either the history or the present watershed moment in the program's 40-year struggle to contain costs and finance quality treatment for Americans with end-stage renal disease. In a timely new paper in the September edition of the journal Health Affairs, researchers chronicle the history of how Medicare has provided one of its most costly services, and point out that a new strategy, if successful, could become a fiscal model for the entire program.

In end-stage , leaves dialysis as the only means of survival. It became one of Medicare's biggest costs after 1972, when the program expanded to care for anyone in the country who needed treatment, regardless of age. Dialysis is expensive and the costs to purchase related anemia drugs is Medicare's single biggest drug expenditure, amounting to $3.9 billion in 2007.

Last year, after decades of trying to balance cost and quality through traditional financing adjustments, Medicare made considerably more dramatic reforms, write the authors from Brown University and the University of Washington. Now policymakers, and consumers will see whether Medicare's simultaneous moves to bundle total costs and discourage lapses in quality will work.

"One of the key and unique aspects of the dialysis reform is the introduction of bundled payments along with pay-for-performance," said lead author Shailender Swaminathan, assistant professor of health services policy and practice. "The twin payment changes offer a very compelling model of policy reform to rein in ."

But at the same time, Swaminathan notes, history teaches that Medicare has encountered costs it could not predict or prevent, and there is no consensus about what level of (a metric of anemia and therefore of treatment performance) is right for ESRD patients. Without clear quality goals, bundled payments could drive providers to undertreat patients and that could create more costs elsewhere in the system.

40 years of policy changes

When Medicare began ESRD coverage, the authors wrote, it did so on a fee-for-service basis. Costs surged with enrollment, for instance growing to 64,000 patients at a cost of $1.8 billion—4 percent of all Medicare spending—in 1982 compared to 16,000 patients at a cost of $229 million in 1973. The number of patients has continued to rise because diabetes and hypertension rates have increased, Swaminathan said, and because improving medical care allows more patients to reach ESRD.

After the first decade, Medicare tried to cap payments for dialysis. Hospital providers received $131 per treatment and clinic providers received $127. For years, providers saw reimbursements drop in inflation-adjusted terms. With payments based on the number of treatment sessions, not their length, the authors wrote, "there was virtually no financial incentive to provide more dialysis."

In the early 1990s as drugs called erythropoietin stimulating agents (ESAs) came to market, Medicare initially paid on a capitated basis. Economically minded providers responded by giving patients lower doses than recommended: 2,400 units rather than 4,000 units.

Medicare quickly moved to a fee-for-service payment for the ESAs, leading to possible overprescription and the huge rise in costs that made ESAs the program's most expensive drug. Providers treating the disease, after all, were limited in how much they could make providing dialysis, but unlimited in what they could reap providing ESAs.

"Fee-for-service reimbursement for the use of the agents, coupled with the decline in real value of the composite rate for dialysis, motivated providers to increase their use of the agents," the authors wrote.

The new regime

Beginning last year, Medicare implemented a new idea to control costs by implementing total bundled payment for providers for dialysis, drugs, and testing. Now providers receive an average of $230 per session for all three.

"In this new payment regime, providers could no longer maximize their Medicare reiumbursements by increasing the use of [ESAs] or other dialysis-related services," the authors wrote.

Meanwhile they also began imposing penalties on providers whose patients had hemoglobin and urea levels that did not meet standards. But the maximum payment reduction is only 2 percent.

"The pay-for-performance program, which was implemented as a complement to payment bundling, might not independently make a serious dent in total health care costs," the authors wrote.

The question instead is whether quality will suffer as overall payments are limited with only a mild deterrent to undertreatment, Swaminathan said. "Going forward, the use of ESAs might fall since the FDA has recently removed the requirement that targeted hemoglobin levels in ESRD patients should at least be 10 grams/deciliter," he said. "This fact plus the incentives provided by bundled payments may see hemoglobin levels decline with a concomitant increase in the rate of blood transfusions, increased hospitalizations and hence increased costs."

But it is also possible that quality levels will remain high and Medicare will have gained a handle on ESRD costs. What would help, Swaminathan said, is better medical evidence of the best hemoglobin levels to target.

"Then, Medicare may be able to pin their pay-for-performance metrics more closely with the evidence," he said. "If that is done, the twin pillars of the recent dialysis payment reform—pay-for-performance and bundling—may become successful."

And then those twin pillars would likely be seen as a model for other services within , he predicted.

Explore further: Patients who don't follow treatments hurt dialysis clinics' pay

Related Stories

Patients who don't follow treatments hurt dialysis clinics' pay

October 24, 2011
Dialysis clinics that provide care to kidney disease patients who cannot or will not follow their prescribed treatments will be penalized under a new Medicare payment system, according to a study appearing in an upcoming ...

Bundling payments to cut health costs proves difficult to achieve, study finds

November 7, 2011
While there is considerable interest in bundling payments to health care providers to encourage them to cut costs, putting the strategy into practice is proving to be more difficult than anticipated.

Recommended for you

High-fat diet in pregnancy can cause mental health problems in offspring

July 21, 2017
A high-fat diet not only creates health problems for expectant mothers, but new research in an animal model suggests it alters the development of the brain and endocrine system of their offspring and has a long-term impact ...

To combat teen smoking, health experts recommend R ratings for movies that depict tobacco use

July 21, 2017
Public health experts have an unusual suggestion for reducing teen smoking: Give just about any movie that depicts tobacco use an automatic R rating.

Opioids and obesity, not 'despair deaths,' raising mortality rates for white Americans

July 20, 2017
Drug-related deaths among middle-aged white men increased more than 25-fold between 1980 and 2014, with the bulk of that spike occurring since the mid-1990s when addictive prescription opioids became broadly available, according ...

Aging Americans enjoy longer life, better health when avoiding three risky behaviors

July 20, 2017
We've heard it before from our doctors and other health experts: Keep your weight down, don't smoke and cut back on the alcohol if you want to live longer.

Parents have critical role in preventing teen drinking

July 20, 2017
Fewer teenagers are drinking alcohol but more needs to be done to curb the drinking habits of Australian school students, based on the findings of the latest study by Adelaide researchers.

Fresh fish oil lowers diabetes risk in rat offspring

July 19, 2017
Fresh fish oil given to overweight pregnant rats prevented their offspring from developing a major diabetes risk factor, Auckland researchers have found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.